Bioscience Platform Companies as Technology/Service Providers and Hybrid Businesses

In this second instalment of our 3-part series, we look at the adolescent and early adulthood stages of bioscience platform companies. What drives the transition to these stages? What are the key success factors during these stages? This article discusses in more detail Stages 2 and 3 of the lifecycle of bioscience platform companies depicted below:

Continue reading “Bioscience Platform Companies as Technology/Service Providers and Hybrid Businesses”

Bioscience Platform Companies and their Lifecycle

What are bioscience platform companies? And how do they eventually develop into fully-fledged product businesses? Most industry participants, commentators and investors recognize and understand start-up biotech companies at one extreme, and fully-fledged pharmaceutical and medical device product companies at the other. However bioscience platform companies are neither. They can be very healthy businesses, yet bereft of product revenues or even profits for many years. And for much of their lifecycle, they can be very difficult for investors to pin a precise valuation on.

Continue reading “Bioscience Platform Companies and their Lifecycle”

BioPharma R&D Focus Paradigms when Payers are the Customers

Most Pharma companies focus their R&D activities by therapeutic area. But in the New Pharma world of Payers as Customers, does this continue to make sense?┬áIn this article, we will look at the history and evolution of therepautic area focus in R&D, highlight today’s new requirements and suggest a pragmatic approach for focusing R&D to create tomorrow’s transformative medicines.
Continue reading “BioPharma R&D Focus Paradigms when Payers are the Customers”